Zacks Investment Research on MSN
Erasca stock surges 42% in a week: Here's what you should know
Shares of Erasca ERAS soared 41.5% in a week. The massive gain was observed after the company announced encouraging early ...
The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...
A research team led by MSK physician-scientist Dr. Piro Lito discovered that certain inhibitors can short-circuit the out-of-control signaling caused by mutations that fuel cancer growth. Each year, ...
Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
Efficacy assessment of a novel pan-RAS inhibitor in KRAS-mutant and wild type colorectal 3D bioprinted organoid tumor tissue. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...
KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback